[1] 邱波,梁卫东,袁良东.小剂量激素、环孢素A、雷公藤多苷联合治疗特发性膜性肾病的临床观察[J].实用药物与临床,2014,17(11):1427~1430. [2] 刘莉华,马胜银.环孢素A治疗特发性膜性肾病的疗效观察[J].安徽医学,2013,34(8):1217~1219. [3] Yang Yang,Wang Chao,Jin Liping,et al. IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study[J].Immunologic research,2016,64(4): 919~930. [4] 肾脏病学实验技术操作规程[J].人民军医,2012,55(10):980. [5] 刘风勋,程根阳,刘章锁.中小剂量环孢素治疗成人特发性膜性肾病疗效观察[J].中国实用医刊,2014,41(8):120~121. [6] 崔琳琳.钙调神经磷酸酶抑制剂治疗特发性膜性肾病的回顾性研究[J].临床肾脏病杂志,2015,15(7):427~432. [7] Rabab Mahmoud,Mohammed El-din Saadi,Tarek Fayad,et al. Role of anti-phospholipase A2 receptor antibodies in monitoring of the clinical status in idiopathic membranous nephropathy in Egyptian patients[J].Journal of The Egyptian Society of Nephrology and Transplantation,2016,16(4): 119~123. [8] 高冬梅,李明旭,余永武.小剂量环孢素A治疗老年膜性肾病临床疗效[J].实用老年医学,2016,31(2):154~157. [9] 陈揭剑.五酯胶囊对特发性膜性肾病患者环孢素A全血浓度的影响研究[J].中国全科医学,2015,18(7):842~845. [10] 李婷,何宇.环孢素A、他克莫司治疗特发性膜性肾病的研究进展[J].山东医药,2015,59(36):93~95. [11] Hofstra Julia M,Debiec Hanna,Short Colin D,et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy[J].American Society of Nephrology,Journal,2012,23(10): 1735~1743. [12] 刘芳,付淑丽.不同剂量激素联合环孢素治疗特发性膜性肾病的临床研究[J].中华肾脏病杂志,2016,32(12):905~912. [13] 何志军,周柱亮.环孢素A联合激素和中药治疗膜性肾病疗效分析[J].中国中西医结合肾病杂志,2011,12(10):900~901. [14] 葛晓,王艳丽,杨莉娅,等.环孢素A治疗特发性膜性肾病的荟萃分析[J].临床荟萃,2012,27(3):196~201. [15] George Kosmadakis,Vasileios Filiopoulos,Christodoulos Georgoulias,et al. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin Ⅱ receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome[J].Scandinavian Journal of Urology and Nephrology,2010,44(4): 251~256. [16] 陈耀中.特发性膜性肾病的治疗进展[J].医学综述,2014,20(7):1245~1247.
2017, Vol. 23 
冀公网安备13080202000677号